Effects of isolated limb perfusion with tumour necrosis factor-alpha on the function of monocytes and T lymphocytes in patients with cancer

European Journal of Clinical Investigation

Volumn 26, Issue 12, 1996, Pages 1085-1091

  Stam, T C ^b   Jongen Lavrencic, M ^b   Eggermont, A M M ^a   Swaak, A J G ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

Author keywords

IL 6; Isolated limb perfusion (ILP); TNF

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8; MELPHALAN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIMB PERFUSION; MALE; MONOCYTE; PRIORITY JOURNAL; REGIONAL PERFUSION; T LYMPHOCYTE;

EID: 0030456192     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1996.480599.x     Document Type: Article

References (24)

1. Creech OJ, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148:616-32.
2. Benckhuijsen C, Kroon BBR, Van Geel AN, Wieberdink J. Regional perfusion treatment with melphalan for melanoma in a limb: evaluation of drug kinetics. Eur J Surg Oncol 1988;14:157-63.
3. Lejeune F, Liénard D, Eggermont A et al. Rationale for using TNF and chemotherapy in regional therapy of melanoma. J Cell Biochem 1994;56:52-61.
4. Eggermont AMM, Liénard D, Schraffordt Koops H, Rosenkaimer F, Lejeune FJ. High dose tumor necrosis factor-I in combination with gamma-interferon and melphalan in isolated perfusion of the limb for irresectable soft tissue sarcomas: a highly effective approach to achieve limb salvage. Contrib Oncol 1994;46:81-8.
5. Swaak AJG, Liénard D, Schraffordt Koops H, Lejeune FJ, Eggermont AMM. Effects of recombinant tumor necrosis factor (rTNFα) in cancer. Observations on the acute phase reaction and immunoglobulin synthesis after high dose recombinant TNFα administration in cancer patients. Eur J Clin Invest 1993;23:812-8.
6. Gelin JL, Moldawer LL, Iresjö BM, Lundholm KG. The role of the adrenals in the acute phase response to interleukin-1 and tumor necrosis factor-α. J Surg Res 1993;54:70-8.
7. Renard N, Liénard D, Lespagnard L, Eggermont AMM, Heimann R, Lejeune FJ. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNFα). Int J Cancer 1994;57:656-63.
8. Renard N, Nooijen P, Schalkwijk L et al. VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha. J Pathol 1995;176:279-87.
9. June CH, Ledbetter JA, Linsley PS, Thompson B. Role of CD28 receptor in T-cell activation. Immunol Today 1990;11:211-6.
10. Bloemena E, Roos MTL, Van Heijst JLAM, Vossen JMJJ, Schellekens PTA. Whole-blood lymphocyte cultures. J Immunol Methods 1989;122:161-7.
11. Helle M, Boeije L, De Groot ER, De Vos A, Aarden LA. Sensitive ELISA for interleukin 6. Detection of IL-6 in biological fluids and sera. J Immunol Methods 1991;138:42-56.
12. Verbrugh CA, Hart MH, Aarden LA, Swaak AJG. Interleukin-8 (IL-8) in synovial fluid of rheumatoid and nonrheumatoid joint effusions. Clin Rheumatol 1993;12:494-9.
13. Van Kooten C, Rensink I, Pascal-Salcedo D, Van Oers R. Aarden LA. Monokine-production by human T-cells; IL-II production restricted to memory T-cells. J Immunol 1991; 146:2654-8.
14. Gérain J, Liénard D, Ewalenko P, Lejeune FJ. High serum levels of TNF-α after its administration for isolated perfusion of the limb. Cytokine 1992;4:585-91.
15. Thorn AK, Alexander HR, Andrich MP, Barker WC, Rosenberg SA, Fraker DL. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma and melphalan. J Clin Oncol 1995;13:264-73.
16. Glaser F, Sannwald GA, Buhr HJ et al. General stress response to conventional and laparoscopic cholecystectomy. Ann Surg 1995;221:372-80.
17. Cruickshank AM, Fraser WD, Burns HJG, Van Damme J, Shenkin A. Response of serum interleukin-6 in patients undergoing elective surgery of varying severity. Clin Sci 1990;79:161-5.
18. Nokta M, Matzke D, Jennings M, Schlick E, Nadler PI, Pollard R. In vivo administration of tumor necrosis factor-α is associated with antiviral activity in human peripheral mononuclear cells. Proc Soc Exp Biol Med 1991;197:144-9.
19. Aulitzky WE, Tilg H, Vogel W et al. Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and interleukin 2. Ann Hematol 1991;62:25-31.
20. Nooijen PRGA, Eggermont AMM, Verbeek MM et al. Transient induction of ELAM-1 expression following TNF based isolated limb perfusion in melanoma and sarcoma patients is not tumor-specific. J Immuno Ther 1996;19:33-44.
21. Pirenne J, Ribbens C, Médot M et al. Adverse effect of abdominal operations on production of interferon-gamma. Eur J Surg 1995;161:77-83.
22. Cope AP, Londei M, Randall Chu N et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor CD-3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994;94:749-60.
23. Lennard TWJ, Shenton BK, Borzotta A et al. The influence of surgical operations on components of the human immune system. Br J Surg 1985;72:771-6.
24. Hamid J, Bancewicz J, Brown R, Ward C, Irving MH, Ford WL. The significance of changes in blood lymphocyte populations following surgical operations. Clin Exp Immunol 1984;56:49-57.